OPK Stock Analysis: Buy, Sell, or Hold?
OPK - Opko Health Inc.
$1.23
-0.12 (-8.89%)
▼
5d:
-18.0%
30d:
-14.58%
90d:
+6.03%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 30, 2026
16d
Smart Money Accumulation
None View Scanner →
Strength: 5.7/10
Get Alerted When OPK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OPK is down 18.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OPK is down 18.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OPK is currently trading at $1.23, which is considered oversold relative to its 30-day fair value range of $1.38 to $1.51.
Technical Outlook: Technically, OPK is in a strong uptrend. The price is currently testing key support at $1.27. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.38 (+255.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OPK is in a strong uptrend. The price is currently testing key support at $1.27. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.38 (+255.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.38 -
$1.51
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.9%)
- BULLISH: Trading 255.7% below Wall St target ($4.38)
- WARNING: Recommendation downgraded due to -18.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.38 -
$1.51
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.28
Resistance Level
$1.57
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.84
Wall Street Target
$4.38
(+255.7%)
Revenue Growth (YoY)
-17.2%
Earnings Growth (YoY)
-12.6%
Profit Margin
-36.6%
Share & Embed Analysis
Last updated: July 13, 2026 6:16 PM ET
Data refreshes hourly during market hours. Next update: 7:16 PM
Data refreshes hourly during market hours. Next update: 7:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OPK showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
John A Paganelli
BUY
10000 shares
2026-03-20
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$591 | 64 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 67 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$157 | 60 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$271 | 54 HOLD |
